Micro Interventional Devices initiates 1st-in-man EU study for its Permaseal
Cardiovascular medical device company Micro Interventional Devices launched a 1st-in-man European clinical study for its Permaseal cardiac closure, a device which combines soft tissue anchors and biocompatible elastomers that form a "web" around the myocardial access site, the company said.
The study will enroll 40 patients at 5 E.U. sites, and MID expects data to be available by Q1 2013.
Symetis closes 1st-in-man trial for Acurate TF aortic bioprosthesis
Swiss medical device maker Symetis completed its 1st-in-man trial of the Acurate TF aortic bioprosthesis and delivery system, a transfemoral aortic valve replacement device.
The company initiated the CE-Mark clinical study in September and hopes the system will win CE Mark approval mid-2013.
Cappella Medical: Positive long-term results for its Sideguard Technology
Medical device maker Cappella Medical unveiled long-term results for its Sideguard coronary sidebranch stent, which is designed to protect sidebranch during treatment of bifurcation disease.